So we think that might improve some of those interfaces with what the customer is trying to do up front of our kits.
Kyle Mikson: Okay. Yeah sounds like a pretty solid and comprehensive update. I look forward to that. All right. Thanks, guys. Appreciate the time.
Jeff Hawkins: Yeah. Thank you, Kyle.
Operator: [Operator Instructions] And your next question comes from the line of Swayampakula Ramakanth with HCW. Your line is now open.
Swayampakula Ramakanth: Thank you. Good afternoon, Jeff and Jeff.
Jeff Hawkins: Hi –
Jeff Keyes: Good afternoon.
Swayampakula Ramakanth: So you are planning to initiate the full launch early next year. And at the same time, also launched a second version of the kit. I’m just trying to understand, is there any reason for us to think one would happen before the other? Or are they going to happen together? And are they dependent on each other in terms of deployment? I’m just trying to understand what just the sequence of events that we should be looking out for?
Jeff Hawkins: Yeah. RK, I would say that the working plan is that we would launch the V2 kit, and then at some period of time shortly after that we would move to the full launch. I would not expect us to move to full launch in advance of the V2 kit, we would sort of stay in the controlled launch we’re in right now. So that’s the way I would think about it as V2 kit. And then, somewhere between right after that to just shortly after that, we would move to the full launch.
Swayampakula Ramakanth: Okay. And what – I don’t I guess you’ll discuss the V2 later. But in general terms, is this going to be anything significantly different or in the sense that you need additional tweaking to the mission as it is now? Or you don’t think there is something majorly different in the kit itself?
Jeff Hawkins: Yeah. So, the machine is not impacted by this at all. The Version 2 kits will be compatible with the existing Platinum Instrument that customers have. This is really improvements to a mix of either the library prep or sequencing reagents or an improvement we’ve made to the chip. We’re not fundamentally changing the underlying to 2M Chip or the hardware itself. It’s really – this will be very seamless for customers, they’ll receive the library prep and sequencing kits and run them with the same Instrument and the same software they’ve been using be fairly seamless change for them. No, no, sort of specific upgrades they need to go through.
Swayampakula Ramakanth: Okay. And then in terms of the data presentations or data publications that you’re expecting this year and early next year. What sort of data should we be expecting from it? And then would that data pretty much portray what the current version of the Instrument can deliver? Or is this going to be something little bit more than that, in a sense, so people like us can kind of think about, okay, what the next version of the Instrument itself could be and what better capabilities can be delivered?
Jeff Hawkins: Sure. So, we talked about the script, the webinar and the presentation from Northwestern that really represents the performance that customers are generating today with the existing Instrument and the existing version of the chemistry. The publication that we discussed, that we expect to be submitted before the end of the year really showing some of the capabilities of the technology in the world of post-translational modifications. But again, using the existing kit and Instrument. As we get into next year, I’d expect in the beginning of the year that any data that comes out would be generated with the kits that are in the market right now. And as the year progresses, more and more of that data coming out with the Version 2 kits. So, there’s always some lag between a version of chemistry and data that gets generated with that. But that’s sort of how I would think about the near-term versus mid-term and throughout ‘24.
